Piggybacking off an earlier deal, Bristol-Myers Squibb has signed another manufacturing agreement with South Korean giant Samsung.
When Big Pharma execs talk up "synergies" to convince shareholders to buy into mergers, they mean, in part, consolidating contractors. And, with all the megadeals rumored and real surfacing over the past week, CROs could be in for a revenue haircut as the drug business realigns.
Global contractor Catalent swung to a profit last quarter thanks to a slight sales increase and some ongoing restructuring, staying the course as it plans to go public in an IPO worth $100 million or more.
Toxicology specialist Harlan Laboratories is looking to tap the growing market for contract research in Oceania, signing a deal with local outfit Invenium Pharmacology to do so.
Cloud-based eClinical outfit Medidata swung to 21% revenue growth in the first quarter, and, after hitting a record value in billings, the New York company is expecting sales to keep rolling in 2014.
Going well beyond the standard sponsor-CRO relationship, Biogen Idec has recruited Quintiles to revamp its clinical development process, giving the contractor a seat at the R&D table to improve trial efficiency.
CRO Theorem Clinical Research has expanded its partnership with eClinical provider Medidata, tapping technology that will allow it to capture data directly from patients.
Chinese CRO WuXi PharmaTech has convinced Steve Yang, head of Asian R&D for AstraZeneca, to jump ship, joining the company as it looks to expand its presence in its home country and abroad.
Global CRO Quintiles is reaching out to software provider OmniComm to replace its Phase I eClinical technology, signing a 5-year deal with the Florida company.
Contract drug developer AMRI will close down its Syracuse, NY, facility by midyear, part of an effort to cut costs and realign its business.
CRO inVentiv Health is teaming up with IntelliCell BioSciences to get the biotech's regenerative medicine candidate through the IND stage, pitching in to develop a novel treatment for osteoarthritis of the knee.
Certara, an informatics-focused pharma contractor, has bought up specialty CRO Synchrogenix, absorbing a company devoted to regulatory writing with hopes of expanding its market share.
On the whole, the CRO industry is increasing its budgets for merit-based pay increases, according to a survey.
Catalent has signed a deal to lend its biologics development technology to China's Zhejiang Hisun Pharmaceuticals and help the drugmaker get working on copies of some top-selling drugs.
Pacira Pharmaceuticals is counting on an expanded indication and swell in demand for its surgical pain treatment, and the biotech has inked a deal with contract manufacturer Patheon to collaborate on production in a multiyear agreement.
Bristol-Myers Squibb is re-upping with market-access outfit DKSH to dial up its commercialization efforts in Asia, extending a deal signed in 2010.
Parexel International is looking to scale up its capabilities in medical imaging for clinical trials, expanding its eClinical outfit and appointing an industry veteran to steer the way.
Clinipace has signed a far-reaching deal with biotech Karyopharm, agreeing to handle a host of studies under a preferred provider arrangement.
Charles River Laboratories has closed its bid for two CROs formerly owned by drug developer Galapagos, trading $179 million up front and up to $7 million down the line for Argenta and BioFocus.
Germany's Evotec subverts the traditional CRO model by cozying up to its development partners with risk-splitting deals, and the company's approach to R&D has attracted Debiopharm and Convergence Pharmaceuticals with programs in cancer and chronic pain.